Raloxifene is not approved for use in men. Clinical trials have focused on post-menopausal women, and safety data in men are insufficient for regulatory endorsement.
Most studies report measurable increases in lumbar spine BMD after 12-24 months of continuous therapy, although fracture risk reduction may become evident earlier.
Unlike estrogen therapy, raloxifene acts as an estrogen antagonist in breast tissue and has been shown to lower the risk of invasive breast cancer in high-risk post-menopausal women.
These symptoms could indicate a deep-vein thrombosis. Seek urgent medical assessment; early diagnosis and treatment are critical.
Yes, calcium and vitamin D are often recommended alongside raloxifene to support overall bone health. There is no known interaction.
In post-menopausal women, raloxifene does not restart menstrual bleeding. It may cause occasional vaginal spotting, which should be reported to a clinician.
Both contain the same active ingredient (60 mg raloxifene) and meet the same regulatory standards for safety, potency, and bioavailability. Inactive ingredients may differ slightly but are generally inert.
Raloxifene does not affect the efficacy of combined oral contraceptives, but contraceptive use is not typically indicated for the post-menopausal population for whom raloxifene is prescribed.
Women with a prior stroke have an increased risk of recurrent cerebrovascular events when using raloxifene. The medication is generally avoided in this subgroup unless benefits clearly outweigh risks.
Yes, but you should carry the original prescription label, a copy of the prescribing clinician’s note, and be aware of any country-specific import restrictions for prescription medicines.
Raloxifene: Generic Medication Overview
Raloxifene is a prescription-only medication marketed in the United Kingdom as a 60 mg oral pill. It belongs to the therapeutic class of selective estrogen receptor modulators (SERMs) and is used primarily to protect bone health in post-menopausal women. The MHRA (Medicines and Healthcare products Regulatory Agency) regulates its availability, and it is supplied by several manufacturers under the same generic name.
Raloxifene binds to estrogen receptors in a tissue-selective manner. In bone tissue it acts as an estrogen agonist, stimulating osteoblast activity and reducing osteoclast-mediated bone resorption. This dual action helps maintain or increase bone mineral density (BMD). In breast and uterine tissue it behaves as an antagonist, limiting estrogen-driven proliferation. The drug is well absorbed after oral administration, with an oral bioavailability of roughly 2 % due to extensive first-pass metabolism. It is metabolised mainly by CYP3A4 and has a half-life of about 28 hours, allowing once-daily dosing. The net effect is a reduction in the risk of vertebral fractures in women with osteoporosis.
In the United Kingdom, raloxifene is approved for:
The medication is intended for women who are at least 1 year post-menopause and who do not have contraindications such as active thromboembolic disease.
Evidence from peer-reviewed studies suggests that raloxifene may have benefit in:
Off-label use requires medical supervision and an individualized risk assessment.
Absolute contraindications
Known or suspected deep-vein thrombosis (DVT) or pulmonary embolism (PE)
Active estrogen-dependent malignant disease (e.g., breast or uterine cancer)
Pregnancy or breastfeeding
Uncontrolled severe liver disease
Relative contraindications
History of stroke or transient ischemic attack
Severe renal impairment (creatinine clearance < 30 mL/min)
Concomitant use of potent CYP3A4 inducers or inhibitors (dose adjustment may be required)
Special populations
Pregnancy/Lactation: Contraindicated due to estrogen-modulating effects that may affect fetal development.
Elderly: May have increased thromboembolic risk; careful assessment needed.
Women with menopausal symptoms: Benefit must be weighed against the potential for hot flashes and clot risk.
Major interactions
Warfarin - raloxifene may enhance anticoagulant effect; INR monitoring recommended.
Tamoxifen - antagonistic action at estrogen receptors may reduce tamoxifen efficacy in breast cancer therapy.
Moderate interactions
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) - may increase plasma levels of raloxifene; dose adjustment may be needed.
CYP3A4 inducers (e.g., rifampicin, phenytoin) - may reduce effectiveness; consider alternative therapy.
Patients should disclose all prescription drugs, over-the-counter products, herbal supplements, and vitamins to their prescriber.
This article provides educational information about raloxifene and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
